公开(公告)号：US20080044476A1

公开(公告)日：2008-02-21

申请号：US11828561

申请日：2007-07-26

申请人： Robert Lyons ,  Michael Robinson ,  John Trogden ,  Scott Whitcup

发明人： Robert Lyons ,  Michael Robinson ,  John Trogden ,  Scott Whitcup

IPC分类号： A61K9/14 ,  A61K31/56 ,  A61K31/715 ,  A61P29/00 ,  A61P19/02 ,  A61K9/00

CPC分类号： A61K9/0019 ,  A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/715 ,  A61K47/02 ,  A61K47/34 ,  A61K47/36 ,  A61K47/40

摘要： Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

摘要翻译： 提供使用这种组合物的粘性制剂和方法，其可用于肌肉内和关节内注射以治疗外周病症。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，粘度在25℃下以0.1 /秒的剪切速率在约140,000cps至约280,000cps的范围内。组合物有利地将曲安奈德颗粒悬浮较长时间。

公开(公告)号：US20070224278A1

公开(公告)日：2007-09-27

申请号：US11741366

申请日：2007-04-27

申请人： Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

发明人： Robert Lyons ,  Michael Robinson ,  James Chang ,  Sam Lam ,  John Trogden ,  Scott Whitcup

IPC分类号： A61K9/14 ,  A61K31/56

CPC分类号： A61K9/0019 ,  A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/715 ,  A61K47/02 ,  A61K47/34 ,  A61K47/36 ,  A61K47/40

摘要： Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes or into a joint are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps t a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

摘要翻译： 提供了曲安奈德组合物，以及使用这种组合物的方法，其可用于注射到人眼玻璃体或关节中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，在25℃下，粘度为约140,000cps至约280,000cps，剪切速率为0.1 /秒。组合物有利地将曲安奈德颗粒悬浮较长时间。

公开(公告)号：US20060141049A1

公开(公告)日：2006-06-29

申请号：US11354415

申请日：2006-02-14

申请人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

发明人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

IPC分类号： A61K31/728 ,  A61K31/695 ,  A61K9/14

CPC分类号： A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K47/36

摘要： Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

摘要翻译： 提供曲安奈德组合物，以及使用这些组合物的方法，其用于注射到人眼的玻璃体中。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 组合物有利地将曲安奈德颗粒悬浮较长时间。

公开(公告)号：US20050101582A1

公开(公告)日：2005-05-12

申请号：US10966764

申请日：2004-10-14

申请人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

发明人： Robert Lyons ,  James Chang ,  John Trogden ,  Scott Whitcup

IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K47/36

CPC分类号： A61K31/58 ,  A61K9/0048 ,  A61K31/573 ,  A61K47/36

摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。

公开(公告)号：US20070227255A1

公开(公告)日：2007-10-04

申请号：US11698296

申请日：2007-01-25

申请人： Neil Goldfine ,  Vladimir Zilberstein ,  David Grundy ,  Andrew Washabaugh ,  Darrell Schlicker ,  Ian Shay ,  Robert Lyons ,  Christopher Craven ,  Christopher Root ,  Mark Windoloski ,  Volker Weiss

发明人： Neil Goldfine ,  Vladimir Zilberstein ,  David Grundy ,  Andrew Washabaugh ,  Darrell Schlicker ,  Ian Shay ,  Robert Lyons ,  Christopher Craven ,  Christopher Root ,  Mark Windoloski ,  Volker Weiss

IPC分类号： G01L1/12

CPC分类号： G01N27/902 ,  G01N27/023 ,  G01N27/24 ,  G01N27/904 ,  G01N27/9046 ,  G01N27/9053

摘要： Observability of damage precursor, damage and usage states, or event occurrence may be enhanced by modifying component materials to include self-monitoring materials or by processing test material to alter the surface properties. The properties of the self monitoring materials, such as magnetic permeability or electrical conductivity, are monitored with electromagnetic sensors and provide greater property variations with component condition than the original component material. Processing includes shot peening or laser welding.

公开(公告)号：US20070077436A1

公开(公告)日：2007-04-05

申请号：US11634285

申请日：2006-12-04

申请人： Basil Naji ,  John Cottier ,  Robert Lyons

发明人： Basil Naji ,  John Cottier ,  Robert Lyons

IPC分类号： B32B9/04

CPC分类号： B28B1/522 ,  B28B7/46 ,  C04B18/08 ,  C04B28/02 ,  C04B2111/00482 ,  C04B2111/00612 ,  E04C2/06 ,  E04F13/02 ,  E04F15/12 ,  Y02W30/92 ,  Y10S106/01 ,  Y10T428/249932 ,  Y10T428/249968 ,  Y10T428/249972 ,  Y10T428/249986 ,  Y10T428/25 ,  Y10T428/265 ,  Y10T428/31504 ,  Y10T428/31667 ,  Y10T442/10 ,  C04B20/008

摘要： The Abstract of the Disclosure filed herewith has replaced the previous Abstract of the Disclosure that begins with the words, “A composite product comprising a substrate layer” with the following paragraph: An exemplary composite product and method of manufacturing is provided. In one embodiment, the method includes dewatering a first slurry through a dewatering belt to form a first substrate layer, applying a first functional layer onto at least a portion of the first substrate layer, and dewatering a second slurry through the dewatering belt to form a second substrate layer. A first side of the second substrate layer may be overlayed onto the first functional layer, and the layers may be cured, and the layers bonded.

摘要翻译： 本文提交的披露摘要已经取代了以下开始于“包含基底层的复合产品”的以前的摘要摘要：提供了一种示例性的复合产品和制造方法。 在一个实施方案中，所述方法包括通过脱水带将第一浆料脱水以形成第一基材层，将第一功能层施加到第一基材层的至少一部分上，以及通过脱水带将第二浆料脱水形成 第二基板层。 第二衬底层的第一侧可以覆盖在第一功能层上，并且可以使层固化，并且层粘合。

公开(公告)号：US20050250737A1

公开(公告)日：2005-11-10

申请号：US11091977

申请日：2005-03-28

申请人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

发明人： Patrick Hughes ,  Laurent Delahaye ,  Michele Boix ,  James Chang ,  Robert Lyons

IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K31/724 ,  A61K47/36

CPC分类号： A61K9/0048 ,  A61K31/573 ,  A61K47/36 ,  A61K47/40

摘要： Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.

摘要翻译： 描述适于施用于人或动物的眼睛内部的药物组合物。 本发明组合物包括一种或多种有效提供相对于现有眼内眼用组合物的毒性降低的成分。 本发明的组合物包含一种或多种治疗剂，其用量在置于眼中时可提供所需的治疗效果，以及一种或多种视黄醛友好的赋形剂，其相对于苯甲醇或聚山梨酸酯80具有降低的毒性。在某些组合物中，赋形剂 组合物的组分包含一种或多种环糊精或环糊精衍生物。 还描述了使用组合物治疗眼睛病症的方法。

公开(公告)号：US20050004074A1

公开(公告)日：2005-01-06

申请号：US10613097

申请日：2003-07-01

申请人： Robert Lyons ,  James Chang

发明人： Robert Lyons ,  James Chang

IPC分类号： A61K9/00 ,  A61K31/557 ,  A61K31/724

CPC分类号： A61K9/0048 ,  A61K31/557 ,  A61K31/724

摘要： This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug. Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.

公开(公告)号：US10991225B1

公开(公告)日：2021-04-27

申请号：US16178863

申请日：2018-11-02

申请人： Robert Lyons

发明人： Robert Lyons

IPC分类号： G08B21/02 ,  B60N2/00 ,  B60R21/015 ,  G08B21/18 ,  B60N2/26 ,  B60R21/01

摘要： A child car seat is disclosed. The car seat has a seat form for accommodating a child. A belt for retaining a child is disposed within the child car seat. A first buckle is operable between a first open position and a second other fastened position, for when fastened fastening the belt to retain a child and for when open facilitating installation and removal of a child from the child car seat. The child car seat also has an integrated interface port for removably retaining a first electronic circuit having communication circuitry for communicating with an automobile. The interface port has electrical conductors for electrically coupling with the electrical circuitry within the first electronic circuit.

公开(公告)号：US20060182783A1

公开(公告)日：2006-08-17

申请号：US11370301

申请日：2006-03-08

申请人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

发明人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

IPC分类号： A61K48/00 ,  A61F2/00

CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40 ,  A61K48/0041

摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂含有选自抗血管生成肽和核酸试剂的组分。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。